With mixed findings from previous studies focused on atopic dermatitis and the use of cognitive behavioral therapy (CBT) as a treatment modality, investigators modified an existing online CBT intervention to account for the lack of clinical psychologists in the dermatological space.
Approximately 14,280 more US patients with psoriasis were estimated to initiate a biologic in Spring than in other seasons, and over 840 more biologic users switched in Spring than in Winter.
A clinical trial found that the prevalence of age-related macular degeneration (AMD) was not associated with the use of metformin.
The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.
Our top coverage from this year’s San Antonio Breast Cancer Symposium (SABCS) included updated data on tamoxifen and trastuzumab deruxtecan, treatments long proven effective in the breast cancer space.
With data collection beginning on January 1, 2023, most health systems are not prepared for CMS’ new glycemia measures, and those that are will likely be floored by the results, according to the chief medical officer at Glytec.
The top 5 most-read rheumatology articles of 2022 covered the topics of management of inflammatory arthritis and new inflammatory protein identification.
The top 5 most-read articles on AJMC.com for 2022 covered COVID-19, the first treatment for repigmentation in vitiligo, migraine care, and vitamin D supplementation for patients with multiple myeloma.
The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses the benefits of de-escalating treatment for patients with multiple myeloma.
The most-read articles in pulmonary arterial hypertension (PAH) for this year ran the gamut of special-interest areas: from treatment costs to pediatric PAH to high-risk patients.
The top 5 most-read content in ophthalmology for 2022 focused on the relationship between aging and visual field reliability, telehealth eye care visits, the link between COVID-19 and dry eye disease, and more.
This year’s top 5 most-viewed videos include topics on eosinophilic esophagitis (EoE), cancer screening awareness, and racial/ethnic and socioeconomic barriers to care.
The American Journal of Managed Care® covered thousands of miles in 2022, virtually and in person, criss-crossing the country and the world to deliver the latest clinical data, trial results, and drug developments.
This year’s most-read articles on dermatology covered the first and only FDA-approved treatment for repigmentation in patients with vitiligo, as well as other therapies for the treatment of acne, hidradenitis suppurativa, and more.
The top 5 pieces of content published on AJMC.com relating to reimbursement issues included 2 on the significance of a California law giving Medicare beneficiaries access to expert oncology care; other articles looked at the work involved in value-based care models and CMS news.
Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the implications of the longer-term follow-up of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) and how age is a factor when considering chemotherapy options.
Throughout 2022, expert interviews on clinical topics covered cytogenetics in multiple myeloma, access to better treatments in diffuse large B-cell lymphoma, and challenges with devices in chronic obstructive pulmonary disease.
The top 5 most-read articles in Parkinson disease for 2022 reviewed interventions for nonmotor symptoms, the health-related impact of exercise and diet, and more.
This year’s most-read articles on chronic obstructive pulmonary disease (COPD) includes researchon early interventions and possible health policy solutions.
Paige Killian, MD, writes about the results of a new study that evaluated the impact of a new program on the health care utilization, costs, and quality outcomes in patients with Medicare Advantage coverage.
This year’s most-viewed HIV content focused on disparities in HIV care, an emerging nonepidemic Kaposi sarcoma subtype, and the need for more research on hepatitis B endurance.
Coverage of the annual meeting of the American Academy of Ophthalmology (AAO) included interviews with experts on thyroid eye disease and anti–vascular endothelial growth factor therapy, as well as breaking research.
The top 5 most listened to podcast episodes on AJMC.com in 2022 provided expert commentary on diabetes, lung disease, health policy, Parkinson disease, and more.
Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content.
A study found that depressive symptoms were associated with a sleep midpoint outside of 2:00-4:00 am.
The top 5 most-read articles about chronic kidney disease (CKD) focused on finerenone benefits, anticoagulants, dementia association, and more.
The top 5 most-read articles on lupus of 2022 included the role of B cells in systemic lupus erythematosus (SLE), the diagnostic journey of women with SLE, future therapies for cutaneous lupus erythematosus (CLE), and more.
This year’s most-read articles on atopic dermatitis (AD) examined AD as a risk factor for other neurological and attention-deficit conditions and efforts to improve the detection of other comorbid conditions associated with the common skin condition.
